Sarolaner,Moxidectin,Pyrantel

Verify with FDA CVM →

671 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
671
Total Reports
23
Deaths Reported
340.0%
Death Rate

Active Ingredients

Sarolaner,Moxidectin,Pyrantel

Administration Routes

UnknownOralTransdermalAuricular (Otic)

Species Affected

Dog 670
Cat 1

Most Affected Breeds

Retriever - Labrador 89
Retriever - Golden 46
Shepherd Dog - German 45
Crossbred Canine/dog 35
Pit Bull 25
Chihuahua 22
Shih Tzu 21
Dog (unknown) 21
Shepherd Dog - Australian 20
Siberian Husky 19

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 264
Vomiting 81
Diarrhoea 56
Lack of efficacy (endoparasite) - tapeworm 51
Lethargy (see also Central nervous system depression in Neurological) 45
Other abnormal test result NOS 40
Lack of efficacy (endoparasite) - hookworm 35
Lack of efficacy (bacteria) - Borrelia 31
Seizure NOS 28
Not eating 22
Overdose 21
Behavioural disorder NOS 19

Outcome Breakdown

Outcome Unknown
446 (66.5%)
Ongoing
131 (19.5%)
Recovered/Normal
71 (10.6%)
Died
12 (1.8%)
Euthanized
11 (1.6%)

Data Summary

Metric Value
Total adverse event reports 671
Reports involving death 23
Case-fatality rate (reported events) 340.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Sarolaner,Moxidectin,Pyrantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 671 adverse event reports referencing Sarolaner,Moxidectin,Pyrantel, including 23 reports in which the animal died — a 340.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Sarolaner,Moxidectin,Pyrantel. Reported administration routes include Unknown, Oral, Transdermal, Auricular (Otic). These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Sarolaner,Moxidectin,Pyrantel reports are Dog (670 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (89), Retriever - Golden (46), Shepherd Dog - German (45) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Sarolaner,Moxidectin,Pyrantel are Lack of efficacy (endoparasite) - heartworm (264), Vomiting (81), Diarrhoea (56), Lack of efficacy (endoparasite) - tapeworm (51). Of the 671 reports with a coded outcome, Outcome Unknown is the leading category at 66.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Sarolaner,Moxidectin,Pyrantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial